Frontlight ResearchEarly access
Taking peoplePhase 1/2
A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)
Key facts
- Who runs it
- CRISPR Therapeutics
- Where
- Australia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 68 people, planned
- Starts
- Dec 2026
- Expected to end
- Jun 2030
- Type of study
- Interventional, 2 groups
- Treatments tested
- CTX460
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Age: ≥18 and ≤75 years
- Able to provide written informed consent
- Diagnosis of AATD with PiZZ homozygous genotype
- Serum total AAT level <11µM in the absence of augmentation
- Emphysema on a CT scan at screening
- A postbronchodilator forced expiratory volume in 1 second (FEV1) ≥30% of predicted
- Body weight ≥50 kg
- All male participants must agree to the use of a highly effective method of contraception and their female partners who are women of childbearing potential (WoCBP) are recommended to use a highly effective method of contraception from consent through 6 months after CTX460 infusion
- In Phase 1, female participants must not be WoCBP
- In Phase 2, All female participants are eligible if they:; Are not pregnant or breastfeeding and; Agree to the use of a highly effective method of contraception, as defined in the protocol, from consent through 6 months after CTX460 infusion or are postmenopausal, as defined in the protocol
- Participants agree to abstain from alcohol for 2 weeks before and 2 weeks after CTX460 infusion
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, contraceptive guidelines, and other trial procedures
Who cannot take part
- Received augmentation therapy within the 6 weeks prior to CTX460 infusion
- Lung or liver transplant or on waiting list for lung or liver transplant
- Participation in another clinical trial with an investigational drug/product within 30 days of screening or <5 half-lives of the investigational agent
- Systemic steroid use within 30 days prior to CTX460 administration; inhaled steroids are permitted
- Prior treatment with therapy using viral vectors or intended to permanently change a participant's DNA (except for CTX460)
- Receipt of LNP vaccines ≤4 weeks prior to screening
- Smokers/vapers (nonsmoking/nonvaping for at least 12 months prior to screening are eligible)
- Participants with alcohol use disorder or alcoholic hepatitis within one year prior to screening
- Moderate to severe lung disease other than COPD that may confound results as per investigator discretion
- Participants with cardiovascular disease
- Exclude participants with an active infection of HBV and HCV
- Exclude participants with uncontrolled HIV
- Participants with a history of medically significant or severe reactions to any LNP-based product, including severe hypersensitivity reactions or anaphylaxis
- History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the trial or pose an additional risk in administering trial drug to the participant
- Active malignancy within past 3 years with the exception of recent basal cell or squamous cell of the skin
- Participants with specified laboratory abnormalities at screening, confirmed by repeat testing when clinically appropriate
- Evidence of significant liver fibrosis/cirrhosis
- In Phase 1 only, females of childbearing potential or breastfeeding females
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A Study of CTX460 in Adults with Emphysema Associated with Severe Alpha-1 Antitrypsin Deficiency (AATD).
The 2 groups in the trial
- Phase 1Treatment being tested
Phase 1 begins with dose escalation based on a single infusion of CTX460.
Treatment: CTX460
- Phase 2Treatment being tested
Recommended Phase 2 dose of CTX460.
Treatment: CTX460
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Official Title: A Phase 1/2 Multicenter, Open-label, First-in-Human Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460, a Lipid Nanoparticle Formulation of SyNTase Editing Components for In Vivo Editing of the Serine Protease Inhibitor A1 (SERPINA1) Gene in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)
- Criteria questions
- Built from NCT07850076, who can take part
- Record updated
- 13 November 2026